Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-07-26
DOI
10.1038/s41467-021-24909-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- (2021) Jerald Sadoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies
- (2021) Maxwell T. Finkelstein et al. Viruses-Basel
- Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
- (2021) Wilfredo F. Garcia-Beltran et al. CELL
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera
- (2021) Daming Zhou et al. CELL
- SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
- (2021) Xiaoying Shen et al. Cell Host & Microbe
- Virus vaccines: proteins prefer prolines
- (2021) Rogier W. Sanders et al. Cell Host & Microbe
- Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
- (2021) Zhuoming Liu et al. Cell Host & Microbe
- Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
- (2021) Allison J. Greaney et al. Cell Host & Microbe
- Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
- (2021) Carolina M. Voloch et al. JOURNAL OF VIROLOGY
- Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
- (2021) Denis Y Logunov et al. LANCET
- Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
- (2021) Dami A. Collier et al. NATURE
- Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein
- (2021) Houriiyah Tegally et al. NATURE
- SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
- (2021) Constantinos Kurt Wibmer et al. NATURE MEDICINE
- Neutralizing Activity of BNT162b2-Elicited Serum
- (2021) Yang Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England
- (2021) Nicholas G. Davies et al. SCIENCE
- Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
- (2021) Alexander Muik et al. SCIENCE
- Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model
- (2021) Fatima Amanat et al. mBio
- Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
- (2021) Kasopefoluwa Y. Oguntuyo et al. mBio
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
- (2021) Markus Hoffmann et al. CELL
- Antibody evasion by the P.1 strain of SARS-CoV-2
- (2021) Wanwisa Dejnirattisai et al. CELL
- Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization
- (2021) Pengfei Wang et al. Cell Host & Microbe
- Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to 5 February
- (2021) Daniel J Grint et al. Eurosurveillance
- Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
- (2021) Sandile Cele et al. NATURE
- Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7
- (2021) Nicholas G. Davies et al. NATURE
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications
- (2021) Salim S. Abdool Karim et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
- (2021) Xing Zhu et al. PLOS BIOLOGY
- Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants
- (2021) Charlie Laffeber et al. JOURNAL OF MOLECULAR BIOLOGY
- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
- (2021) Meng Yuan et al. SCIENCE
- Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
- (2021) Yongfei Cai et al. SCIENCE
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
- (2020) Daniel Wrapp et al. SCIENCE
- A serological assay to detect SARS-CoV-2 seroconversion in humans
- (2020) Fatima Amanat et al. NATURE MEDICINE
- A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
- (2020) M. Eugenia Dieterle et al. Cell Host & Microbe
- Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice
- (2020) James Brett Case et al. Cell Host & Microbe
- Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2
- (2020) James Brett Case et al. Cell Host & Microbe
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
- (2020) Kizzmekia S. Corbett et al. NATURE
- Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
- (2020) Alina Baum et al. SCIENCE
- Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic
- (2020) Maciej F. Boni et al. Nature Microbiology
- Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
- (2020) Amin Addetia et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
- (2020) Denis Y Logunov et al. LANCET
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- CoV3D: a database of high resolution coronavirus protein structures
- (2020) Ragul Gowthaman et al. NUCLEIC ACIDS RESEARCH
- Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
- (2020) Rinke Bos et al. npj Vaccines
- Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
- (2020) Allison J. Greaney et al. Cell Host & Microbe
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
- (2020) Bina Choi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
- (2020) Yfat Yahalom-Ronen et al. Nature Communications
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
- GISAID: Global initiative on sharing all influenza data – from vision to reality
- (2017) Yuelong Shu et al. Eurosurveillance
- Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
- (2017) Jesper Pallesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficient and Robust Paramyxoviridae Reverse Genetics Systems
- (2017) Shannon M. Beaty et al. mSphere
- Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
- (2015) Nicholas E. Webb et al. Nature Communications
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started